KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Tax Provisions (2016 - 2025)

Jazz Pharmaceuticals has reported Tax Provisions over the past 14 years, most recently at $5.0 million for Q4 2025.

  • Quarterly results put Tax Provisions at $5.0 million for Q4 2025, up 108.65% from a year ago — trailing twelve months through Dec 2025 was -$312.5 million (down 242.11% YoY), and the annual figure for FY2025 was -$272.4 million, down 198.03%.
  • Tax Provisions for Q4 2025 was $5.0 million at Jazz Pharmaceuticals, up from -$242.4 million in the prior quarter.
  • Over the last five years, Tax Provisions for JAZZ hit a ceiling of $228.6 million in Q2 2021 and a floor of -$242.4 million in Q3 2025.
  • Median Tax Provisions over the past 5 years was -$17.2 million (2025), compared with a mean of -$21.5 million.
  • Biggest five-year swings in Tax Provisions: soared 317.5% in 2021 and later tumbled 3160.0% in 2023.
  • Jazz Pharmaceuticals' Tax Provisions stood at -$12.5 million in 2021, then crashed by 701.09% to -$100.0 million in 2022, then soared by 66.92% to -$33.1 million in 2023, then crashed by 74.99% to -$57.9 million in 2024, then surged by 108.65% to $5.0 million in 2025.
  • The last three reported values for Tax Provisions were $5.0 million (Q4 2025), -$242.4 million (Q3 2025), and -$17.2 million (Q2 2025) per Business Quant data.